The October 1 EOP2 meeting is a binary catalyst. A positive outcome aligning on Phase 3 design would de-risk RAD101 and likely drive significant upside for this small-cap biotech. Monitor for any pre-meeting FDA briefing documents or analyst notes. The Siemens partnership provides manufacturing support, reducing execution risk.
Price Chart
Executive Summary
Radiopharm Theranostics announced an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 trial design for RAD101, a novel imaging agent for recurrent brain metastases. The Phase 2b trial met its primary endpoint with 93% concordance with MRI. This is a key regulatory milestone for a clinical-stage company with a $37M market cap, bringing RAD101 closer to a pivotal trial and potential commercialization.
Key Facts
- End-of-Phase 2 meeting with FDA scheduled for October 1, 2026
- Phase 2b trial met primary endpoint with 93% concordance with MRI across all evaluable lesions
- RAD101 has FDA Fast Track Designation
- Company on track to be Phase 3 ready by year-end 2026
- Partnership with Siemens Healthineers for manufacturing and distribution of RAD101 for Phase 3 trial
- Over 300,000 patients diagnosed annually with cerebral metastases in the U.S.
Financial Impact
Regulatory milestone for a $37M market cap company; successful Phase 3 could unlock significant value in a large market (300,000+ annual U.S. patients)
Risk Factors
- FDA may request additional data or a different trial design, delaying Phase 3
- Phase 3 trial may fail to replicate Phase 2b results
- Company is pre-revenue with limited cash runway; may need to raise capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345992 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9600 | awaiting T+5 | — | $0.9100 (−5.21%) |
Oct 26, 2026 1d ago | 6-K | $0.9485 | awaiting T+5 | — | $0.9100 (−4.06%) |
Oct 20, 2026 7d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9100 (−8.08%) |
Oct 14, 2026 12d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9100 (−15.74%) |
Oct 5, 2026 22d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9100 (−28.35%) |
Oct 1, 2026 26d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9100 (−38.51%) |
Sep 30, 2026 27d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9100 (−43.83%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9100 (+42.11%) |
Sep 22, 2026 5w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9100 (−44.85%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9100 (−54.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers